ation of cyp450 enzymes. upon initiation of stelara ® in patients who are receiving concomitant cyp450 substrates, particularly those with a narrow therapeutic index, monitoring for therapeutic effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) should be considered and the individual dose of the drug adjusted as needed [see clinical pharmacology (12.3) ] . 7.3 allergen immunotherapy stelara ® has not been evaluated in patients who have undergone allergy immunotherapy. stelara ® may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy. therefore, caution should be exercised in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis.

ents with moderately to severely active crohn's disease. 1.4 ulcerative colitis stelara ® is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

er clinically significant hypersensitivity reactions may occur. ( 5.5 ) posterior reversible encephalopathy syndrome (pres) : if pres is suspected, treat promptly and discontinue stelara ® . ( 5.6 ) noninfectious pneumonia : cases of interstitial pneumonia, eosinophilic pneumonia and cryptogenic organizing pneumonia have been reported during post-approval use of stelara ® . if diagnosis is confirmed, discontinue stelara ® and institute appropriate treatment. ( 5.9 ) 5.1 infections stelara ® may increase the risk of infections and reactivation of latent infections. serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving stelara ® [see adverse reactions (6.1 , 6.3) ] . serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical studies included the following: psoriasis : diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis and urinary tract infections. psoriatic arthritis : cholecystitis. crohn's disease : anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeria meningitis. ulcerative colitis : gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeriosis. treatment with stelara ® should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. consider the risks and benefits of treatment prior to initiating use of stelara ® in patients with a chronic infection or a history of recurrent infection. instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with stelara ® and consider discontinuing stelara ® for serious or clinically significant infections until the infection resolves or is adequately treated. 5.2 theoretical risk for vulnerability to particular infections individuals genetically deficient in il-12/il-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), salmonella (including nontyphi strains), and bacillus calmette-guerin (bcg) vaccinations. serious infections and fatal outcomes have been reported in such patients. it is not known whether patients with pharmacologic blockade of il-12/il-23 from treatment with stelara ® may be susceptible to these types of infections. appropriate diagnostic testing should be considered, e.g., tissue culture, stool culture, as dictated by clinical circumstances. 5.3 pre-treatment evaluation for tuberculosis evaluate patients for tuberculosis infection prior to initiating treatment with stelara ® . do not administer stelara ® to patients with active tuberculosis infection. initiate treatment of latent tuberculosis prior to administering stelara ® . consider anti-tuberculosis therapy prior to initiation of stelara ® in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. closely monitor patients receiving stelara ® for signs and symptoms of active tuberculosis during and after treatment. 5.4 malignancies stelara ® is an immunosuppressant and may increase the risk of malignancy. malignancies were reported among subjects who received stelara ® in clinical studies [see adverse reactions (6.1) ] . in rodent models, inhibition of il-12/il-23p40 increased the risk of malignancy [see nonclinical toxicology (13) ] . the safety of stelara ® has not been evaluated in patients who have a history of malignancy or who have a known malignancy. there have been post-marketing reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving stelara ® who had pre-existing risk factors for developing non-melanoma skin cancer. all patients receiving stelara ® should be monitored for the appearance of non-melanoma skin cancer. patients greater than 60 years of age, those with a medical history of prolonged immunosuppressant therapy and those with a history of puva treatment should be followed closely [see adverse reactions (6.1) ] . 5.5 hypersensitivity reactions hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with stelara ® [see adverse reactions (6.1 , 6.3) ] . if an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue stelara ® . 5.6 posterior reversible encephalopathy syndrome (pres) two cases of posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), were reported in clinical trials. cases have also been reported in postmarketing experience in patients with psoriasis, psoriatic arthritis and crohn's disease. clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with pres a few days to several months after ustekinumab initiation. a few cases reported latency of a year or longer. patients recovered with supportive care following withdrawal of ustekinumab. monitor all patients treated with stelara ® for signs and symptoms of pres. if pres is suspected, promptly administer appropriate treatment and discontinue stelara ® . 5.7 immunizations prior to initiating therapy with stelara ® , patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. patients being treated with stelara ® should not receive live vaccines. bcg vaccines should not be given during treatment with stelara ® or for one year prior to initiating treatment or one year following discontinuation of treatment. caution is advised when administering live vaccines to household contacts of patients receiving stelara ® because of the potential risk for shedding from the household contact and transmission to patient. non-live vaccinations received during a course of stelara ® may not elicit an immune response sufficient to prevent disease. 5.8 concomitant therapies in clinical studies of psoriasis the safety of stelara ® in combination with other biologic immunosuppressive agents or phototherapy was not evaluated. ultraviolet-induced skin cancers developed earlier and more frequently in mice genetically manipulated to be deficient in both il-12 and il-23 or il-12 alone [see concomitant therapies (7.1) , nonclinical toxicology (13.1) ] . 5.9 noninfectious pneumonia cases of interstitial pneumonia, eosinophilic pneumonia and cryptogenic organizing pneumonia have been reported during post-approval use of stelara ® . clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. serious outcomes have included respiratory failure and prolonged hospitalization. patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. if diagnosis is confirmed, discontinue stelara ® and institute appropriate treatment [see postmarketing experience (6.3) ] .

iasis weighing greater than 100 kg, the recommended dosage is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks. psoriatic arthritis pediatric (6 to 17 years old) subcutaneous recommended dosage ( 2.2 ): weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter. weight range (kilograms) dosage regimen less than 60 kg 0.75 mg/kg 60 kg or more 45 mg greater than 100 kg with co-existent moderate-to-severe plaque psoriasis 90 mg crohn's disease and ulcerative colitis initial adult intravenous recommended dosage ( 2.3 ) : a single intravenous infusion using weight-based dosing: weight range (kilograms) recommended dosage up to 55 kg 260 mg (2 vials) greater than 55 kg to 85 kg 390 mg (3 vials) greater than 85 kg 520 mg (4 vials) crohn's disease and ulcerative colitis maintenance adult subcutaneous recommended dosage ( 2.3 ) : a subcutaneous 90 mg dose 8 weeks after the initial intravenous dose, then every 8 weeks thereafter. 2.1 psoriasis subcutaneous adult dosage regimen for patients weighing 100 kg or less, the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. for patients weighing more than 100 kg, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. in subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. however, 90 mg resulted in greater efficacy in these subjects [see clinical studies (14) ] . subcutaneous pediatric dosage regimen administer stelara ® subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. the recommended dose of stelara ® for pediatric patients (6–17 years old) based on body weight is shown below (table 1). table 1: recommended dose of stelara ® for subcutaneous injection in pediatric patients (6–17 years old) with psoriasis body weight of patient at the time of dosing recommended dose less than 60 kg 0.75 mg/kg 60 kg to 100 kg 45 mg more than 100 kg 90 mg for pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in table 2; withdraw the appropriate volume from the single-dose vial. table 2: injection volumes of stelara ® 45 mg/0.5 ml single-dose vials for pediatric patients (6–17 years old) with psoriasis and pediatric patients (6–17 years old) with psoriatic arthritis refer to 2.2 psoriatic arthritis; subcutaneous pediatric dosage regimen. weighing less than 60 kg body weight (kg) at the time of dosing dose (mg) volume of injection (ml) 15 11.3 0.12 16 12.0 0.13 17 12.8 0.14 18 13.5 0.15 19 14.3 0.16 20 15.0 0.17 21 15.8 0.17 22 16.5 0.18 23 17.3 0.19 24 18.0 0.20 25 18.8 0.21 26 19.5 0.22 27 20.3 0.22 28 21.0 0.23 29 21.8 0.24 30 22.5 0.25 31 23.3 0.26 32 24 0.27 33 24.8 0.27 34 25.5 0.28 35 26.3 0.29 36 27 0.3 37 27.8 0.31 38 28.5 0.32 39 29.3 0.32 40 30 0.33 41 30.8 0.34 42 31.5 0.35 43 32.3 0.36 44 33 0.37 45 33.8 0.37 46 34.5 0.38 47 35.3 0.39 48 36 0.4 49 36.8 0.41 50 37.5 0.42 51 38.3 0.42 52 39 0.43 53 39.8 0.44 54 40.5 0.45 55 41.3 0.46 56 42 0.46 57 42.8 0.47 58 43.5 0.48 59 44.3 0.49 2.2 psoriatic arthritis subcutaneous adult dosage regimen the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. for patients with co-existent moderate-to-severe plaque psoriasis weighing more than 100 kg, the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. subcutaneous pediatric dosage regimen administer stelara ® subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. the recommended dose of stelara ® for pediatric patients (6 to 17 years old) with psoriatic arthritis, based on body weight, is shown below (table 3). table 3: recommended dose of stelara ® for subcutaneous injection in pediatric patients (6 to 17 years old) with psoriatic arthritis body weight of patient at the time of dosing recommended dose less than 60 kg for pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in table 2; withdraw the appropriate volume from the single-dose vial. 0.75 mg/kg 60 kg or more 45 mg greater than 100 kg with co-existent moderate-to-severe plaque psoriasis 90 mg 2.3 crohn's disease and ulcerative colitis intravenous induction adult dosage regimen a single intravenous infusion dose of stelara ® using the weight-based dosage regimen specified in table 4 [see instructions for dilution of stelara® 130 mg vial for intravenous infusion (2.6) ] . table 4: initial intravenous dosage of stelara ® body weight of patient at the time of dosing dose number of 130 mg/26 ml (5 mg/ml) stelara ® vials 55 kg or less 260 mg 2 more than 55 kg to 85 kg 390 mg 3 more than 85 kg 520 mg 4 subcutaneous maintenance adult dosage regimen the recommended maintenance dosage is a subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter. 2.4 general considerations for administration stelara ® is intended for use under the guidance and supervision of a physician. stelara ® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. the appropriate dose should be determined by a healthcare provider using the patient's current weight at the time of dosing. in pediatric patients, it is recommended that stelara ® be administered by a healthcare provider. if a physician determines that it is appropriate, a patient may self-inject or a caregiver may inject stelara ® after proper training in subcutaneous injection technique. patients should be instructed to follow the directions provided in the medication guide [see medication guide ] . the needle cover on the prefilled syringe contains dry natural rubber (a derivative of latex). the needle cover should not be handled by persons sensitive to latex. it is recommended that each injection be administered at a different anatomic location (such as upper arms, gluteal regions, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated. when using the single-dose vial, a 1 ml syringe with a 27 gauge, ½ inch needle is recommended. prior to administration, visually inspect stelara ® for particulate matter and discoloration. stelara ® is a colorless to light yellow solution and may contain a few small translucent or white particles. do not use stelara ® if it is discolored or cloudy, or if other particulate matter is present. stelara ® does not contain preservatives; therefore, discard any unused product remaining in the vial and/or syringe. 2.5 instructions for administration of stelara ® prefilled syringes equipped with needle safety guard refer to the diagram below for the provided instructions. to prevent premature activation of the needle safety guard, do not touch the needle guard activation clips at any time during use. hold the body and remove the needle cover. do not hold the plunger or plunger head while removing the needle cover or the plunger may move. do not use the prefilled syringe if it is dropped without the needle cover in place . inject stelara ® subcutaneously as recommended [see dosage and administration (2.1 , 2.2 , 2.3) ] . inject all of the medication by pushing in the plunger until the plunger head is completely between the needle guard wings. injection of the entire prefilled syringe contents is necessary to activate the needle guard . after injection, maintain the pressure on the plunger head and remove the needle from the skin. slowly take your thumb off the plunger head to allow the empty syringe to move up until the entire needle is covered by the needle guard, as shown by the illustration below: used syringes should be placed in a puncture-resistant container. image image image 2.6 preparation and administration of stelara ® 130 mg/26 ml (5 mg/ml) vial for intravenous infusion (crohn's disease and ulcerative colitis) stelara ® solution for intravenous infusion must be diluted, prepared and infused by a healthcare professional using aseptic technique. calculate the dose and the number of stelara ® vials needed based on patient weight (table 4). each 26 ml vial of stelara ® contains 130 mg of ustekinumab. withdraw, and then discard a volume of the 0.9% sodium chloride injection, usp from the 250 ml infusion bag equal to the volume of stelara ® to be added (discard 26 ml sodium chloride for each vial of stelara ® needed, for 2 vials- discard 52 ml, for 3 vials- discard 78 ml, 4 vials- discard 104 ml). alternatively, a 250 ml infusion bag containing 0.45% sodium chloride injection, usp may be used. withdraw 26 ml of stelara ® from each vial needed and add it to the 250 ml infusion bag. the final volume in the infusion bag should be 250 ml. gently mix. visually inspect the diluted solution before infusion. do not use if visibly opaque particles, discoloration or foreign particles are observed. infuse the diluted solution over a period of at least one hour. once diluted, the infusion should be completely administered within eight hours of the dilution in the infusion bag. use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometer). do not infuse stelara ® concomitantly in the same intravenous line with other agents. stelara ® does not contain preservatives. each vial is for single use only. discard any remaining solution. dispose any unused medicinal product in accordance with local requirements. storage if necessary, the diluted infusion solution may be kept at room temperature up to 25°c (77°f) for up to 7 hours. storage time at room temperature begins once the diluted solution has been prepared. the infusion should be completed within 8 hours after the dilution in the infusion bag (cumulative time after preparation including the storage and the infusion period). do not freeze. discard any unused portion of the infusion solution.

ions, contact janssen biotech, inc. at 1-800-janssen (1-800-526-7736) or fda at 1-800-fda-1088 or www.fda.gov/medwatch. 6.1 clinical trials experience because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. adult subjects with plaque psoriasis the safety data reflect exposure to stelara ® in 3117 adult psoriasis subjects, including 2414 exposed for at least 6 months, 1855 exposed for at least one year, 1653 exposed for at least two years, 1569 exposed for at least three years, 1482 exposed for at least four years and 838 exposed for at least five years. table 5 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the stelara ® groups than the placebo group during the placebo-controlled period of ps study 1 and ps study 2 [see clinical studies (14) ] . table 5: adverse reactions reported by ≥1% of subjects through week 12 in ps study 1 and ps study 2 stelara ® placebo 45 mg 90 mg subjects treated 665 664 666 nasopharyngitis 51 (8%) 56 (8%) 49 (7%) upper respiratory tract infection 30 (5%) 36 (5%) 28 (4%) headache 23 (3%) 33 (5%) 32 (5%) fatigue 14 (2%) 18 (3%) 17 (3%) diarrhea 12 (2%) 13 (2%) 13 (2%) back pain 8 (1%) 9 (1%) 14 (2%) dizziness 8 (1%) 8 (1%) 14 (2%) pharyngolaryngeal pain 7 (1%) 9 (1%) 12 (2%) pruritus 9 (1%) 10 (2%) 9 (1%) injection site erythema 3 (<1%) 6 (1%) 13 (2%) myalgia 4 (1%) 7 (1%) 8 (1%) depression 3 (<1%) 8 (1%) 4 (1%) adverse reactions that occurred at rates less than 1% in the controlled period of ps studies 1 and 2 through week 12 included: cellulitis, herpes zoster, diverticulitis and certain injection site reactions (pain, swelling, pruritus, induration, hemorrhage, bruising, and irritation). one case of pres occurred during adult plaque psoriasis clinical studies [see warnings and precautions (5.6) ] . infections in the placebo-controlled period of clinical studies of psoriasis subjects (average follow-up of 12.6 weeks for placebo-treated subjects and 13.4 weeks for stelara ® -treated subjects), 27% of stelara ® -treated subjects reported infections (1.39 per subject-year of follow-up) compared with 24% of placebo-treated subjects (1.21 per subject-year of follow-up). serious infections occurred in 0.3% of stelara ® -treated subjects (0.01 per subject-year of follow-up) and in 0.4% of placebo-treated subjects (0.02 per subject-year of follow-up) [see warnings and precautions (5.1) ] . in the controlled and non-controlled portions of psoriasis clinical studies (median follow-up of 3.2 years), representing 8998 subject-years of exposure, 72.3% of stelara ® -treated subjects reported infections (0.87 per subject-years of follow-up). serious infections were reported in 2.8% of subjects (0.01 per subject-years of follow-up). malignancies in the controlled and non-controlled portions of psoriasis clinical studies (median follow-up of 3.2 years, representing 8998 subject-years of exposure), 1.7% of stelara ® -treated subjects reported malignancies excluding non-melanoma skin cancers (0.60 per hundred subject-years of follow-up). non-melanoma skin cancer was reported in 1.5% of stelara ® -treated subjects (0.52 per hundred subject-years of follow-up) [see warnings and precautions (5.4) ] . the most frequently observed malignancies other than non-melanoma skin cancer during the clinical studies were: prostate, melanoma, colorectal and breast. malignancies other than non-melanoma skin cancer in stelara ® -treated patients during the controlled and uncontrolled portions of studies were similar in type and number to what would be expected in the general u.s. population according to the seer database (adjusted for age, gender and race). 1 pediatric subjects with plaque psoriasis the safety of stelara ® was assessed in two studies of pediatric subjects with moderate to severe plaque psoriasis. ps study 3 evaluated safety for up to 60 weeks in 110 adolescents (12 to 17 years old). ps study 4 evaluated safety for up to 56 weeks in 44 children (6 to 11 years old). the safety profile in pediatric subjects was similar to the safety profile from studies in adults with plaque psoriasis. psoriatic arthritis the safety of stelara ® was assessed in 927 subjects in two randomized, double-blind, placebo-controlled studies in adults with active psoriatic arthritis (psa). the overall safety profile of stelara ® in subjects with psa was consistent with the safety profile seen in adult psoriasis clinical studies. a higher incidence of arthralgia, nausea, and dental infections was observed in stelara ® -treated subjects when compared with placebo-treated subjects (3% vs. 1% for arthralgia and 3% vs. 1% for nausea; 1% vs. 0.6% for dental infections) in the placebo-controlled portions of the psa clinical studies. crohn's disease the safety of stelara ® was assessed in 1407 subjects with moderately to severely active crohn's disease (crohn's disease activity index [cdai] greater than or equal to 220 and less than or equal to 450) in three randomized, double-blind, placebo-controlled, parallel-group, multicenter studies. these 1407 subjects included 40 subjects who received a prior investigational intravenous ustekinumab formulation but were not included in the efficacy analyses. in studies cd-1 and cd-2 there were 470 subjects who received stelara ® 6 mg/kg as a weight-based single intravenous induction dose and 466 who received placebo [see dosage and administration (2.3) ] . subjects who were responders in either study cd-1 or cd-2 were randomized to receive a subcutaneous maintenance regimen of either 90 mg stelara ® every 8 weeks, or placebo for 44 weeks in study cd-3. subjects in these 3 studies may have received other concomitant therapies including aminosalicylates, immunomodulatory agents [azathioprine (aza), 6-mercaptopurine (6-mp), methotrexate (mtx)], oral corticosteroids (prednisone or budesonide), and/or antibiotics for their crohn's disease [see clinical studies (14.4) ] . the overall safety profile of stelara ® was consistent with the safety profile seen in the adult psoriasis and psoriatic arthritis clinical studies. common adverse reactions in studies cd-1 and cd-2 and in study cd-3 are listed in tables 6 and 7, respectively. table 6: common adverse reactions through week 8 in studies cd-1 and cd-2 occurring in ≥3% of stelara ® -treated subjects and higher than placebo placebo stelara ® 6 mg/kg single intravenous induction dose n=466 n=470 vomiting 3% 4% other less common adverse reactions reported in subjects in studies cd-1 and cd-2 included asthenia (1% vs 0.4%), acne (1% vs 0.4%), and pruritus (2% vs 0.4%). table 7: common adverse reactions through week 44 in study cd-3 occurring in ≥3% of stelara ® -treated subjects and higher than placebo placebo stelara ® 90 mg subcutaneous maintenance dose every 8 weeks n=133 n=131 nasopharyngitis 8% 11% injection site erythema 0 5% vulvovaginal candidiasis/mycotic infection 1% 5% bronchitis 3% 5% pruritus 2% 4% urinary tract infection 2% 4% sinusitis 2% 3% infections in patients with crohn's disease, serious or other clinically significant infections included anal abscess, gastroenteritis, and pneumonia. in addition, listeria meningitis and ophthalmic herpes zoster were reported in one patient each [see warnings and precautions (5.1) ] . malignancies with up to one year of treatment in the crohn's disease clinical studies, 0.2% of stelara ® -treated subjects (0.36 events per hundred patient-years) and 0.2% of placebo-treated subjects (0.58 events per hundred patient-years) developed non-melanoma skin cancer. malignancies other than non-melanoma skin cancers occurred in 0.2% of stelara ® -treated subjects (0.27 events per hundred patient-years) and in none of the placebo-treated subjects. hypersensitivity reactions including anaphylaxis in cd studies, two patients reported hypersensitivity reactions following stelara ® administration. one patient experienced signs and symptoms consistent with anaphylaxis (tightness of the throat, shortness of breath, and flushing) after a single subcutaneous administration (0.1% of patients receiving subcutaneous stelara ® ). in addition, one patient experienced signs and symptoms consistent with or related to a hypersensitivity reaction (chest discomfort, flushing, urticaria, and increased body temperature) after the initial intravenous stelara ® dose (0.08% of patients receiving intravenous stelara ® ). these patients were treated with oral antihistamines or corticosteroids and in both cases symptoms resolved within an hour. ulcerative colitis the safety of stelara ® was evaluated in two randomized, double-blind, placebo-controlled clinical studies (uc-1 [iv induction] and uc-2 [sc maintenance]) in 960 adult subjects with moderately to severely active ulcerative colitis [see clinical studies (14.5) ] . the overall safety profile of stelara ® in patients with ulcerative colitis was consistent with the safety profile seen across all approved indications. adverse reactions reported in at least 3% of stelara ® -treated subjects and at a higher rate than placebo were: induction (uc-1): nasopharyngitis (7% vs 4%). maintenance (uc-2): nasopharyngitis (24% vs 20%), headache (10% vs 4%), abdominal pain (7% vs 3%), influenza (6% vs 5%), fever (5% vs. 4%), diarrhea (4% vs 1%), sinusitis (4% vs 1%), fatigue (4% vs 2%), and nausea (3% vs 2%). infections in patients with ulcerative colitis, serious or other clinically significant infections included gastroenteritis and pneumonia. in addition, listeriosis and ophthalmic herpes zoster were reported in one patient each [see warnings and precautions (5.1) ] . malignancies with up to one year of treatment in the ulcerative colitis clinical studies, 0.4% of stelara ® -treated subjects (0.48 events per hundred patient-years) and 0.0% of placebo-treated subjects (0.00 events per hundred patient-years) developed non-melanoma skin cancer. malignancies other than non-melanoma skin cancers occurred in 0.5% of stelara ® -treated subjects (0.64 events per hundred patient-years) and 0.2% of placebo-treated subjects (0.40 events per hundred patient-years). 6.2 immunogenicity as with all therapeutic proteins, there is potential for immunogenicity. the detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications and underlying disease. for these reasons, comparison of the incidence of antibodies to ustekinumab in the studies described below with the incidence of antibodies to other products may be misleading. approximately 6 to 12.4% of subjects treated with stelara ® in psoriasis and psoriatic arthritis clinical studies developed antibodies to ustekinumab, which were generally low-titer. in psoriasis clinical studies, antibodies to ustekinumab were associated with reduced or undetectable serum ustekinumab concentrations and reduced efficacy. in psoriasis studies, the majority of subjects who were positive for antibodies to ustekinumab had neutralizing antibodies. in crohn's disease and ulcerative colitis clinical studies, 2.9% and 4.6% of subjects, respectively, developed antibodies to ustekinumab when treated with stelara ® for approximately one year. no apparent association between the development of antibodies to ustekinumab and the development of injection site reactions was seen. 6.3 postmarketing experience the following adverse reactions have been reported during post-approval of stelara ® . because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to stelara ® exposure. immune system disorders: serious hypersensitivity reactions (including anaphylaxis and angioedema), other hypersensitivity reactions (including rash and urticaria) [see warnings and precautions (5.5) ] . infections and infestations: lower respiratory tract infection (including opportunistic fungal infections and tuberculosis) [see warnings and precautions (5.1)] . neurological disorders: posterior reversible encephalopathy syndrome (pres) [see warnings and precautions (5.6) ]. respiratory, thoracic and mediastinal disorders: interstitial pneumonia, eosinophilic pneumonia and cryptogenic organizing pneumonia [see warnings and precautions (5.9) ]. skin reactions : pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis.

ation of cyp450 enzymes. upon initiation of stelara ® in patients who are receiving concomitant cyp450 substrates, particularly those with a narrow therapeutic index, monitoring for therapeutic effect (e.g., for warfarin) or drug concentration (e.g., for cyclosporine) should be considered and the individual dose of the drug adjusted as needed [see clinical pharmacology (12.3) ] . 7.3 allergen immunotherapy stelara ® has not been evaluated in patients who have undergone allergy immunotherapy. stelara ® may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy. therefore, caution should be exercised in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis.

inform a drug associated risk. animal data ustekinumab was tested in two embryo-fetal development toxicity studies in cynomolgus monkeys. no teratogenic or other adverse developmental effects were observed in fetuses from pregnant monkeys that were administered ustekinumab subcutaneously twice weekly or intravenously weekly during the period of organogenesis. serum concentrations of ustekinumab in pregnant monkeys were greater than 100 times the serum concentration in patients treated subcutaneously with 90 mg of ustekinumab weekly for 4 weeks. in a combined embryo-fetal development and pre- and post-natal development toxicity study, pregnant cynomolgus monkeys were administered subcutaneous doses of ustekinumab twice weekly at exposures greater than 100 times the human subcutaneous exposure from the beginning of organogenesis to day 33 after delivery. neonatal deaths occurred in the offspring of one monkey administered ustekinumab at 22.5 mg/kg and one monkey dosed at 45 mg/kg. no ustekinumab-related effects on functional, morphological, or immunological development were observed in the neonates from birth through six months of age. 8.2 lactation risk summary there are no data on the presence of ustekinumab in human milk, the effects on the breastfed infant, or the effects on milk production. ustekinumab was present in the milk of lactating monkeys administered ustekinumab. due to species-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk. maternal igg is known to be present in human milk. published data suggest that the systemic exposure to a breastfed infant is expected to be low because ustekinumab is a large molecule and is degraded in the gastrointestinal tract. however, if ustekinumab is transferred into human milk the effects of local exposure in the gastrointestinal tract are unknown. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for stelara ® and any potential adverse effects on the breastfed child from stelara ® or from the underlying maternal condition. 8.4 pediatric use plaque psoriasis the safety and effectiveness of stelara ® have been established for the treatment of moderate to severe plaque psoriasis in pediatric patients 6 to 17 years old. use of stelara ® in patients 12 to less than 17 years old is supported by evidence from a multicenter, randomized, 60-week trial (ps study 3) that included a 12-week, double-blind, placebo-controlled, parallel-group portion, in 110 pediatric subjects 12 years and older [see adverse reactions (6.1) , clinical studies (14.2) ] . use of stelara ® in patients 6 to 11 years old is supported by evidence from an open-label, single-arm, efficacy, safety and pharmacokinetics study (ps study 4) in 44 subjects [see adverse reactions (6.1) , pharmacokinetics (12.3) ] . the safety and effectiveness of stelara ® have not been established in pediatric patients less than 6 years of age with psoriasis. psoriatic arthritis the safety and effectiveness of stelara ® have been established for treatment of psoriatic arthritis in pediatric patients 6 to 17 years old. use of stelara ® in these age groups is supported by evidence from adequate and well controlled studies of stelara ® in adults with psoriasis and psa, pharmacokinetic data from adult patients with psoriasis, adult patients with psa and pediatric patients with psoriasis, and safety data from two clinical studies in 44 pediatric patients 6 to 11 years old with psoriasis and 110 pediatric patients 12 to 17 years old with psoriasis. the observed pre-dose (trough) concentrations are generally comparable between adult patients with psoriasis, adult patients with psa and pediatric patients with psoriasis, and the pk exposure is expected to be comparable between adult and pediatric patients with psa [see adverse reactions (6.1) , clinical pharmacology (12.3) , and clinical studies (14.1 , 14.2 , 14.3) ]. the safety and effectiveness of stelara ® have not been established in pediatric patients less than 6 years old with psoriatic arthritis. crohn's disease and ulcerative colitis the safety and effectiveness of stelara ® have not been established in pediatric patients with crohn's disease or ulcerative colitis. 8.5 geriatric use of the 6709 patients exposed to stelara ® , a total of 340 were 65 years or older (183 patients with psoriasis, 65 patients with psoriatic arthritis, 58 patients with crohn's disease and 34 patients with ulcerative colitis), and 40 patients were 75 years or older. although no overall differences in safety or efficacy were observed between older and younger patients, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients.

. animal data ustekinumab was tested in two embryo-fetal development toxicity studies in cynomolgus monkeys. no teratogenic or other adverse developmental effects were observed in fetuses from pregnant monkeys that were administered ustekinumab subcutaneously twice weekly or intravenously weekly during the period of organogenesis. serum concentrations of ustekinumab in pregnant monkeys were greater than 100 times the serum concentration in patients treated subcutaneously with 90 mg of ustekinumab weekly for 4 weeks. in a combined embryo-fetal development and pre- and post-natal development toxicity study, pregnant cynomolgus monkeys were administered subcutaneous doses of ustekinumab twice weekly at exposures greater than 100 times the human subcutaneous exposure from the beginning of organogenesis to day 33 after delivery. neonatal deaths occurred in the offspring of one monkey administered ustekinumab at 22.5 mg/kg and one monkey dosed at 45 mg/kg. no ustekinumab-related effects on functional, morphological, or immunological development were observed in the neonates from birth through six months of age.

ment of psoriatic arthritis in pediatric patients 6 to 17 years old. use of stelara ® in these age groups is supported by evidence from adequate and well controlled studies of stelara ® in adults with psoriasis and psa, pharmacokinetic data from adult patients with psoriasis, adult patients with psa and pediatric patients with psoriasis, and safety data from two clinical studies in 44 pediatric patients 6 to 11 years old with psoriasis and 110 pediatric patients 12 to 17 years old with psoriasis. the observed pre-dose (trough) concentrations are generally comparable between adult patients with psoriasis, adult patients with psa and pediatric patients with psoriasis, and the pk exposure is expected to be comparable between adult and pediatric patients with psa [see adverse reactions (6.1) , clinical pharmacology (12.3) , and clinical studies (14.1 , 14.2 , 14.3) ]. the safety and effectiveness of stelara ® have not been established in pediatric patients less than 6 years old with psoriatic arthritis. crohn's disease and ulcerative colitis the safety and effectiveness of stelara ® have not been established in pediatric patients with crohn's disease or ulcerative colitis.

decrease was observed in the expression of mrna of its molecular targets il-12 and il-23 in lesional skin biopsies measured at baseline and up to two weeks post-treatment in subjects with psoriasis. ulcerative colitis in both study uc-1 (induction) and study uc-2 (maintenance), a positive relationship was observed between exposure and rates of clinical remission, clinical response, and endoscopic improvement. the response rate approached a plateau at the ustekinumab exposures associated with the recommended dosing regimen for maintenance treatment [see clinical studies (14.5) ] . 12.3 pharmacokinetics absorption in adult subjects with psoriasis, the median time to reach the maximum serum concentration (t max ) was 13.5 days and 7 days, respectively, after a single subcutaneous administration of 45 mg (n=22) and 90 mg (n=24) of ustekinumab. in healthy subjects (n=30), the median t max value (8.5 days) following a single subcutaneous administration of 90 mg of ustekinumab was comparable to that observed in subjects with psoriasis. following multiple subcutaneous doses of stelara ® in adult subjects with psoriasis, steady-state serum concentrations of ustekinumab were achieved by week 28. the mean (±sd) steady-state trough serum ustekinumab concentrations were 0.69 ± 0.69 mcg/ml for patients less than or equal to 100 kg receiving a 45 mg dose and 0.74 ± 0.78 mcg/ml for patients greater than 100 kg receiving a 90 mg dose. there was no apparent accumulation in serum ustekinumab concentration over time when given subcutaneously every 12 weeks. following the recommended intravenous induction dose, mean ±sd peak serum ustekinumab concentration was 125.2 ± 33.6 mcg/ml in patients with crohn's disease, and 129.1 ± 27.6 mcg/ml in patients with ulcerative colitis. starting at week 8, the recommended subcutaneous maintenance dosing of 90 mg ustekinumab was administered every 8 weeks. steady state ustekinumab concentration was achieved by the start of the second maintenance dose. there was no apparent accumulation in ustekinumab concentration over time when given subcutaneously every 8 weeks. mean ±sd steady-state trough concentration was 2.5 ± 2.1 mcg/ml in patients with crohn's disease, and 3.3 ± 2.3 mcg/ml in patients with ulcerative colitis for 90 mg ustekinumab administered every 8 weeks. distribution population pharmacokinetic analyses showed that the volume of distribution of ustekinumab in the central compartment was 2.7 l (95% ci: 2.69, 2.78) in patients with crohn's disease and 3.0 l (95% ci: 2.96, 3.07) in patients with ulcerative colitis. the total volume of distribution at steady-state was 4.6 l in patients with crohn's disease and 4.4 l in patients with ulcerative colitis. elimination the mean (±sd) half-life ranged from 14.9 ± 4.6 to 45.6 ± 80.2 days across all psoriasis studies following subcutaneous administration. population pharmacokinetic analyses showed that the clearance of ustekinumab was 0.19 l/day (95% ci: 0.185, 0.197) in patients with crohn's disease and 0.19 l/day (95% ci: 0.179, 0.192) in patients with ulcerative colitis with an estimated median terminal half-life of approximately 19 days for both ibd (crohn's disease and ulcerative colitis) populations. these results indicate the pharmacokinetics of ustekinumab were similar between patients with crohn's disease and ulcerative colitis. metabolism the metabolic pathway of ustekinumab has not been characterized. as a human igg1κ monoclonal antibody, ustekinumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous igg. specific populations weight when given the same dose, subjects with psoriasis or psoriatic arthritis weighing more than 100 kg had lower median serum ustekinumab concentrations compared with those subjects weighing 100 kg or less. the median trough serum concentrations of ustekinumab in subjects of higher weight (greater than 100 kg) in the 90 mg group were comparable to those in subjects of lower weight (100 kg or less) in the 45 mg group. age: geriatric population a population pharmacokinetic analysis (n=106/1937 patients with psoriasis greater than or equal to 65 years old) was performed to evaluate the effect of age on the pharmacokinetics of ustekinumab. there were no apparent changes in pharmacokinetic parameters (clearance and volume of distribution) in subjects older than 65 years old. age: pediatric population following multiple recommended doses of stelara ® in pediatric subjects 6 to 17 years of age with psoriasis, steady-state serum concentrations of ustekinumab were achieved by week 28. at week 28, the mean ±sd steady-state trough serum ustekinumab concentrations were 0.36 ± 0.26 mcg/ml and 0.54 ± 0.43 mcg/ml, respectively, in pediatric subjects 6 to 11 years of age and adolescent subjects 12 to 17 years of age. overall, the observed steady-state ustekinumab trough concentrations in pediatric patients with psoriasis were within the range of those observed for adult patients with psoriasis and adult patients with psa after administration of stelara ® . drug interaction studies the effects of il-12 or il-23 on the regulation of cyp450 enzymes were evaluated in an in vitro study using human hepatocytes, which showed that il-12 and/or il-23 at levels of 10 ng/ml did not alter human cyp450 enzyme activities (cyp1a2, 2b6, 2c9, 2c19, 2d6, or 3a4). however, the clinical relevance of in vitro data has not been established [see drug interactions (7.3) ] . no in vivo drug interaction studies have been conducted with stelara ® . population pharmacokinetic analyses indicated that the clearance of ustekinumab was not impacted by concomitant mtx, nsaids, and oral corticosteroids, or prior exposure to a tnf blocker in patients with psoriatic arthritis. in patients with crohn's disease and ulcerative colitis, population pharmacokinetic analyses did not indicate changes in ustekinumab clearance with concomitant use of corticosteroids or immunomodulators (aza, 6-mp, or mtx); and serum ustekinumab concentrations were not impacted by concomitant use of these medications.

he recommended intravenous induction dose, mean ±sd peak serum ustekinumab concentration was 125.2 ± 33.6 mcg/ml in patients with crohn's disease, and 129.1 ± 27.6 mcg/ml in patients with ulcerative colitis. starting at week 8, the recommended subcutaneous maintenance dosing of 90 mg ustekinumab was administered every 8 weeks. steady state ustekinumab concentration was achieved by the start of the second maintenance dose. there was no apparent accumulation in ustekinumab concentration over time when given subcutaneously every 8 weeks. mean ±sd steady-state trough concentration was 2.5 ± 2.1 mcg/ml in patients with crohn's disease, and 3.3 ± 2.3 mcg/ml in patients with ulcerative colitis for 90 mg ustekinumab administered every 8 weeks. distribution population pharmacokinetic analyses showed that the volume of distribution of ustekinumab in the central compartment was 2.7 l (95% ci: 2.69, 2.78) in patients with crohn's disease and 3.0 l (95% ci: 2.96, 3.07) in patients with ulcerative colitis. the total volume of distribution at steady-state was 4.6 l in patients with crohn's disease and 4.4 l in patients with ulcerative colitis. elimination the mean (±sd) half-life ranged from 14.9 ± 4.6 to 45.6 ± 80.2 days across all psoriasis studies following subcutaneous administration. population pharmacokinetic analyses showed that the clearance of ustekinumab was 0.19 l/day (95% ci: 0.185, 0.197) in patients with crohn's disease and 0.19 l/day (95% ci: 0.179, 0.192) in patients with ulcerative colitis with an estimated median terminal half-life of approximately 19 days for both ibd (crohn's disease and ulcerative colitis) populations. these results indicate the pharmacokinetics of ustekinumab were similar between patients with crohn's disease and ulcerative colitis. metabolism the metabolic pathway of ustekinumab has not been characterized. as a human igg1κ monoclonal antibody, ustekinumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous igg. specific populations weight when given the same dose, subjects with psoriasis or psoriatic arthritis weighing more than 100 kg had lower median serum ustekinumab concentrations compared with those subjects weighing 100 kg or less. the median trough serum concentrations of ustekinumab in subjects of higher weight (greater than 100 kg) in the 90 mg group were comparable to those in subjects of lower weight (100 kg or less) in the 45 mg group. age: geriatric population a population pharmacokinetic analysis (n=106/1937 patients with psoriasis greater than or equal to 65 years old) was performed to evaluate the effect of age on the pharmacokinetics of ustekinumab. there were no apparent changes in pharmacokinetic parameters (clearance and volume of distribution) in subjects older than 65 years old. age: pediatric population following multiple recommended doses of stelara ® in pediatric subjects 6 to 17 years of age with psoriasis, steady-state serum concentrations of ustekinumab were achieved by week 28. at week 28, the mean ±sd steady-state trough serum ustekinumab concentrations were 0.36 ± 0.26 mcg/ml and 0.54 ± 0.43 mcg/ml, respectively, in pediatric subjects 6 to 11 years of age and adolescent subjects 12 to 17 years of age. overall, the observed steady-state ustekinumab trough concentrations in pediatric patients with psoriasis were within the range of those observed for adult patients with psoriasis and adult patients with psa after administration of stelara ® . drug interaction studies the effects of il-12 or il-23 on the regulation of cyp450 enzymes were evaluated in an in vitro study using human hepatocytes, which showed that il-12 and/or il-23 at levels of 10 ng/ml did not alter human cyp450 enzyme activities (cyp1a2, 2b6, 2c9, 2c19, 2d6, or 3a4). however, the clinical relevance of in vitro data has not been established [see drug interactions (7.3) ] . no in vivo drug interaction studies have been conducted with stelara ® . population pharmacokinetic analyses indicated that the clearance of ustekinumab was not impacted by concomitant mtx, nsaids, and oral corticosteroids, or prior exposure to a tnf blocker in patients with psoriatic arthritis. in patients with crohn's disease and ulcerative colitis, population pharmacokinetic analyses did not indicate changes in ustekinumab clearance with concomitant use of corticosteroids or immunomodulators (aza, 6-mp, or mtx); and serum ustekinumab concentrations were not impacted by concomitant use of these medications.

ot evaluated in mated females. no effects on fertility were observed in female mice that were administered an analogous il-12/il-23p40 antibody by subcutaneous administration at doses up to 50 mg/kg, twice weekly, prior to and during early pregnancy. 13.2 animal toxicology and/or pharmacology in a 26-week toxicology study, one out of 10 monkeys subcutaneously administered 45 mg/kg ustekinumab twice weekly for 26 weeks had a bacterial infection.

les. no effects on fertility were observed in female mice that were administered an analogous il-12/il-23p40 antibody by subcutaneous administration at doses up to 50 mg/kg, twice weekly, prior to and during early pregnancy.

he proportion of subjects who achieved at least a 75% reduction in pasi score (pasi 75) from baseline to week 12 and treatment success (cleared or minimal) on the physician's global assessment (pga). the pga is a 6-category scale ranging from 0 (cleared) to 5 (severe) that indicates the physician's overall assessment of psoriasis focusing on plaque thickness/induration, erythema, and scaling. in both studies, subjects in all treatment groups had a median baseline pasi score ranging from approximately 17 to 18. baseline pga score was marked or severe in 44% of subjects in ps study 1 and 40% of subjects in ps study 2. approximately two-thirds of all subjects had received prior phototherapy, 69% had received either prior conventional systemic or biologic therapy for the treatment of psoriasis, with 56% receiving prior conventional systemic therapy and 43% receiving prior biologic therapy. a total of 28% of subjects had a history of psoriatic arthritis. clinical response the results of ps study 1 and ps study 2 are presented in table 8 below. table 8: clinical outcomes ps study 1 and ps study 2 week 12 ps study 1 ps study 2 stelara ® stelara ® placebo 45 mg 90 mg placebo 45 mg 90 mg subjects randomized 255 255 256 410 409 411 pasi 75 response 8 (3%) 171 (67%) 170 (66%) 15 (4%) 273 (67%) 311 (76%) pga of cleared or minimal 10 (4%) 151 (59%) 156 (61%) 18 (4%) 277 (68%) 300 (73%) examination of age, gender, and race subgroups did not identify differences in response to stelara ® among these subgroups. in subjects who weighed 100 kg or less, response rates were similar with both the 45 mg and 90 mg doses; however, in subjects who weighed greater than 100 kg, higher response rates were seen with 90 mg dosing compared with 45 mg dosing (table 9 below). table 9: clinical outcomes by weight ps study 1 and ps study 2 ps study 1 ps study 2 stelara ® stelara ® placebo 45 mg 90 mg placebo 45 mg 90 mg subjects randomized 255 255 256 410 409 411 pasi 75 response at week 12 patients were dosed with study medication at weeks 0 and 4. ≤100 kg 4% 74% 65% 4% 73% 78% 6/166 124/168 107/164 12/290 218/297 225/289 >100 kg 2% 54% 68% 3% 49% 71% 2/89 47/87 63/92 3/120 55/112 86/121 pga of cleared or minimal at week 12 ≤100 kg 4% 64% 63% 5% 74% 75% 7/166 108/168 103/164 14/290 220/297 216/289 >100 kg 3% 49% 58% 3% 51% 69% 3/89 43/87 53/92 4/120 57/112 84/121 subjects in ps study 1 who were pasi 75 responders at both weeks 28 and 40 were re-randomized at week 40 to either continued dosing of stelara ® (stelara ® at week 40) or to withdrawal of therapy (placebo at week 40). at week 52, 89% (144/162) of subjects re-randomized to stelara ® treatment were pasi 75 responders compared with 63% (100/159) of subjects re-randomized to placebo (treatment withdrawal after week 28 dose). the median time to loss of pasi 75 response among the subjects randomized to treatment withdrawal was 16 weeks. 14.2 adolescent subjects with plaque psoriasis a multicenter, randomized, double blind, placebo-controlled study (ps study 3) enrolled 110 adolescent subjects 12 to 17 years of age with a minimum bsa involvement of 10%, a pasi score greater than or equal to 12, and a pga score greater than or equal to 3, who were candidates for phototherapy or systemic therapy and whose disease was inadequately controlled by topical therapy. subjects were randomized to receive placebo (n = 37), the recommended dose of stelara ® (n = 36), or one-half the recommended dose of stelara ® (n = 37) by subcutaneous injection at weeks 0 and 4 followed by dosing every 12 weeks (q12w). the recommended dose of stelara ® was 0.75 mg/kg for subjects weighing less than 60 kg, 45 mg for subjects weighing 60 kg to 100 kg, and 90 mg for subjects weighing greater than 100 kg. at week 12, subjects who received placebo were crossed over to receive stelara ® at the recommended dose or one-half the recommended dose. of the adolescent subjects, approximately 63% had prior exposure to phototherapy or conventional systemic therapy and approximately 11% had prior exposure to biologics. the endpoints were the proportion of patients who achieved a pga score of cleared (0) or minimal (1), pasi 75, and pasi 90 at week 12. subjects were followed for up to 60 weeks following first administration of study agent. clinical response the efficacy results at week 12 for ps study 3 are presented in table 10. table 10: summary of efficacy endpoints in the adolescent psoriasis study at week 12 ps study 3 placebo n (%) stelara ® using the weight-based dosage regimen specified in table 1 and table 2. n (%) n 37 36 pga pga of cleared (0) or minimal (1) 2 (5.4%) 25 (69.4%) pasi pasi 75 responders 4 (10.8%) 29 (80.6%) pasi 90 responders 2 (5.4%) 22 (61.1%) 14.3 psoriatic arthritis the safety and efficacy of stelara ® was assessed in 927 patients (psa study 1, n=615; psa study 2, n=312), in two randomized, double-blind, placebo-controlled studies in adult patients 18 years of age and older with active psa (≥5 swollen joints and ≥5 tender joints) despite non-steroidal anti-inflammatory (nsaid) or disease modifying antirheumatic (dmard) therapy. patients in these studies had a diagnosis of psa for at least 6 months. patients with each subtype of psa were enrolled, including polyarticular arthritis with the absence of rheumatoid nodules (39%), spondylitis with peripheral arthritis (28%), asymmetric peripheral arthritis (21%), distal interphalangeal involvement (12%) and arthritis mutilans (0.5%). over 70% and 40% of the patients, respectively, had enthesitis and dactylitis at baseline. patients were randomized to receive treatment with stelara ® 45 mg, 90 mg, or placebo subcutaneously at weeks 0 and 4 followed by every 12 weeks (q12w) dosing. approximately 50% of patients continued on stable doses of mtx (≤25 mg/week). the primary endpoint was the percentage of patients achieving acr 20 response at week 24. in psa study 1 and psa study 2, 80% and 86% of the patients, respectively, had been previously treated with dmards. in psa study 1, previous treatment with anti-tumor necrosis factor (tnf)-α agent was not allowed. in psa study 2, 58% (n=180) of the patients had been previously treated with tnf blocker, of whom over 70% had discontinued their tnf blocker treatment for lack of efficacy or intolerance at any time. clinical response in both studies, a greater proportion of patients achieved acr 20, acr 50 and pasi 75 response in the stelara ® 45 mg and 90 mg groups compared to placebo at week 24 (see table 11 ). acr 70 responses were also higher in the stelara ® 45 mg and 90 mg groups, although the difference was only numerical (p=ns) in study 2. responses were consistent in patients treated with stelara ® alone or in combination with methotrexate. responses were similar in patients regardless of prior tnfα exposure. table 11: acr 20, acr 50, acr 70 and pasi 75 responses in psa study 1 and psa study 2 at week 24 psa study 1 psa study 2 stelara ® stelara ® placebo 45 mg 90 mg placebo 45 mg 90 mg number of patients randomized 206 205 204 104 103 105 acr 20 response, n (%) 47 (23%) 87 (42%) 101 (50%) 21 (20%) 45 (44%) 46 (44%) acr 50 response, n (%) 18 (9%) 51 (25%) 57 (28%) 7 (7%) 18 (17%) 24 (23%) acr 70 response, n (%) 5 (2%) 25 (12%) 29 (14%) 3 (3%) 7 (7%) 9 (9%) number of patients with ≥ 3% bsa number of patients with ≥ 3% bsa psoriasis skin involvement at baseline 146 145 149 80 80 81 pasi 75 response, n (%) 16 (11%) 83 (57%) 93 (62%) 4 (5%) 41 (51%) 45 (56%) the percent of patients achieving acr 20 responses by visit is shown in figure 1. figure 1: percent of patients achieving acr 20 response through week 24 psa study 1 the results of the components of the acr response criteria are shown in table 12. table 12: mean change from baseline in acr components at week 24 psa study 1 stelara ® placebo (n = 206) 45 mg (n = 205) 90 mg (n = 204) number of swollen joints number of swollen joints counted (0–66) baseline 15 12 13 mean change at week 24 -3 -5 -6 number of tender joints number of tender joints counted (0–68) baseline 25 22 23 mean change at week 24 -4 -8 -9 patient's assessment of pain visual analogue scale; 0= best, 10=worst. baseline 6.1 6.2 6.6 mean change at week 24 -0.5 -2.0 -2.6 patient global assessment baseline 6.1 6.3 6.4 mean change at week 24 -0.5 -2.0 -2.5 physician global assessment baseline 5.8 5.7 6.1 mean change at week 24 -1.4 -2.6 -3.1 disability index (haq) disability index of the health assessment questionnaire; 0 = best, 3 = worst, measures the patient's ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity. baseline 1.2 1.2 1.2 mean change at week 24 -0.1 -0.3 -0.4 crp (mg/dl) crp: (normal range 0.0–1.0 mg/dl) baseline 1.6 1.7 1.8 mean change at week 24 0.01 -0.5 -0.8 an improvement in enthesitis and dactylitis scores was observed in each stelara ® group compared with placebo at week 24. figure 1 physical function stelara ® -treated patients showed improvement in physical function compared to patients treated with placebo as assessed by haq-di at week 24. in both studies, the proportion of haq-di responders (≥0.3 improvement in haq-di score) was greater in the stelara ® 45 mg and 90 mg groups compared to placebo at week 24. 14.4 crohn's disease stelara ® was evaluated in three randomized, double-blind, placebo-controlled clinical studies in adult patients with moderately to severely active crohn's disease (crohn's disease activity index [cdai] score of 220 to 450). there were two 8-week intravenous induction studies (cd-1 and cd-2) followed by a 44-week subcutaneous randomized withdrawal maintenance study (cd-3) representing 52 weeks of therapy. patients in cd-1 had failed or were intolerant to treatment with one or more tnf blockers, while patients in cd-2 had failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed treatment with a tnf blocker. studies cd-1 and cd-2 in studies cd-1 and cd-2, 1409 patients were randomized, of whom 1368 (cd-1, n=741; cd-2, n=627) were included in the final efficacy analysis. induction of clinical response (defined as a reduction in cdai score of greater than or equal to 100 points or cdai score of less than 150) at week 6 and clinical remission (defined as a cdai score of less than 150) at week 8 were evaluated. in both studies, patients were randomized to receive a single intravenous administration of stelara ® at either approximately 6 mg/kg, placebo (see table 4 ), or 130 mg (a lower dose than recommended). in study cd-1, patients had failed or were intolerant to prior treatment with a tnf blocker: 29% patients had an inadequate initial response (primary non-responders), 69% responded but subsequently lost response (secondary non-responders) and 36% were intolerant to a tnf blocker. of these patients, 48% failed or were intolerant to one tnf blocker and 52% had failed 2 or 3 prior tnf blockers. at baseline and throughout the study, approximately 46% of the patients were receiving corticosteroids and 31% of the patients were receiving immunomodulators (aza, 6-mp, mtx). the median baseline cdai score was 319 in the stelara ® approximately 6 mg/kg group and 313 in the placebo group. in study cd-2, patients had failed or were intolerant to prior treatment with corticosteroids (81% of patients), at least one immunomodulator (6-mp, aza, mtx; 68% of patients), or both (49% of patients). additionally, 69% never received a tnf blocker and 31% previously received but had not failed a tnf blocker. at baseline, and throughout the study, approximately 39% of the patients were receiving corticosteroids and 35% of the patients were receiving immunomodulators (aza, 6-mp, mtx). the median baseline cdai score was 286 in the stelara ® and 290 in the placebo group. in these induction studies, a greater proportion of patients treated with stelara ® (at the recommended dose of approximately 6 mg/kg dose) achieved clinical response at week 6 and clinical remission at week 8 compared to placebo (see table 13 for clinical response and remission rates). clinical response and remission were significant as early as week 3 in stelara ® -treated patients and continued to improve through week 8. table 13: induction of clinical response and remission in cd-1 patient population consisted of patients who failed or were intolerant to tnf blocker therapy and cd-2 patient population consisted of patients who failed or were intolerant to corticosteroids or immunomodulators (e.g., 6-mp, aza, mtx) and previously received but not failed a tnf blocker or were never treated with a tnf blocker. cd-1 n = 741 cd-2 n = 627 placebo n = 247 stelara ® infusion dose of stelara ® using the weight-based dosage regimen specified in table 4. n = 249 treatment difference and 95% ci placebo n = 209 stelara ® n = 209 treatment difference and 95% ci clinical remission is defined as cdai score < 150; clinical response is defined as reduction in cdai score by at least 100 points or being in clinical remission: 70 point response is defined as reduction in cdai score by at least 70 points clinical response (100 point), week 6 53 (21%) 84 (34%) 0.001≤ p < 0.01 12% (4%, 20%) 60 (29%) 116 (56%) p < 0.001 27% (18%, 36%) clinical remission, week 8 18 (7%) 52 (21%) 14% (8%, 20%) 41 (20%) 84 (40%) 21% (12%, 29%) clinical response (100 point), week 8 50 (20%) 94 (38%) 18% (10%, 25%) 67 (32%) 121 (58%) 26% (17%, 35%) 70 point response, week 6 75 (30%) 109 (44%) 13% (5%, 22%) 81 (39%) 135 (65%) 26% (17%, 35%) 70 point response, week 3 67 (27%) 101 (41%) 13% (5%, 22%) 66 (32%) 106 (51%) 19% (10%, 28%) study cd-3 the maintenance study (cd-3), evaluated 388 patients who achieved clinical response (≥100 point reduction in cdai score) at week 8 with either induction dose of stelara ® in studies cd-1 or cd-2. patients were randomized to receive a subcutaneous maintenance regimen of either 90 mg stelara ® every 8 weeks or placebo for 44 weeks (see table 14 ). table 14: clinical response and remission in cd-3 (week 44; 52 weeks from initiation of the induction dose) placebo the placebo group consisted of patients who were in response to stelara ® and were randomized to receive placebo at the start of maintenance therapy. 90 mg stelara ® every 8 weeks treatment difference and 95% ci n = 131 patients who achieved clinical response to stelara ® at the end of the induction study. n = 128 clinical remission is defined as cdai score < 150; clinical response is defined as reduction in cdai of at least 100 points or being in clinical remission clinical remission 47 (36%) 68 (53%) p < 0.01 17% (5%, 29%) clinical response 58 (44%) 76 (59%) 0.01≤ p < 0.05 15% (3%, 27%) clinical remission in patients in remission at the start of maintenance therapy patients in remission at the end of maintenance therapy who were in remission at the start of maintenance therapy. this does not account for any other time point during maintenance therapy. 36/79 (46%) 52/78 (67%) 21% (6%, 36%) at week 44, 47% of patients who received stelara ® were corticosteroid-free and in clinical remission, compared to 30% of patients in the placebo group. at week 0 of study cd-3, 34/56 (61%) stelara ® -treated patients who previously failed or were intolerant to tnf blocker therapies were in clinical remission and 23/56 (41%) of these patients were in clinical remission at week 44. in the placebo arm, 27/61 (44%) patients were in clinical remission at week 0 while 16/61 (26%) of these patients were in remission at week 44. at week 0 of study cd-3, 46/72 (64%) stelara ® -treated patients who had previously failed immunomodulator therapy or corticosteroids (but not tnf blockers) were in clinical remission and 45/72 (63%) of these patients were in clinical remission at week 44. in the placebo arm, 50/70 (71%) of these patients were in clinical remission at week 0 while 31/70 (44%) were in remission at week 44. in the subset of these patients who were also naïve to tnf blockers, 34/52 (65%) of stelara ® -treated patients were in clinical remission at week 44 as compared to 25/51 (49%) in the placebo arm. patients who were not in clinical response 8 weeks after stelara ® induction were not included in the primary efficacy analyses for study cd-3; however, these patients were eligible to receive a 90 mg subcutaneous injection of stelara ® upon entry into study cd-3. of these patients, 102/219 (47%) achieved clinical response eight weeks later and were followed for the duration of the study. 14.5 ulcerative colitis stelara ® was evaluated in two randomized, double-blind, placebo-controlled clinical studies [uc-1 and uc-2 (nct02407236)] in adult patients with moderately to severely active ulcerative colitis who had an inadequate response to or failed to tolerate a biologic (i.e., tnf blocker and/or vedolizumab), corticosteroids, and/or 6-mp or aza therapy. the 8-week intravenous induction study (uc-1) was followed by the 44-week subcutaneous randomized withdrawal maintenance study (uc-2) for a total of 52 weeks of therapy. disease assessment was based on the mayo score, which ranged from 0 to 12 and has four subscores that were each scored from 0 (normal) to 3 (most severe): stool frequency, rectal bleeding, findings on centrally-reviewed endoscopy, and physician global assessment. moderately to severely active ulcerative colitis was defined at baseline (week 0) as mayo score of 6 to 12, including a mayo endoscopy subscore ≥2. an endoscopy score of 2 was defined by marked erythema, absent vascular pattern, friability, erosions; and a score of 3 was defined by spontaneous bleeding, ulceration. at baseline, patients had a median mayo score of 9, with 84% of patients having moderate disease (mayo score 6–10) and 15% having severe disease (mayo score 11–12). patients in these studies may have received other concomitant therapies including aminosalicylates, immunomodulatory agents (aza, 6-mp, or mtx), and oral corticosteroids (prednisone). study uc-1 in uc-1, 961 patients were randomized at week 0 to a single intravenous administration of stelara ® of approximately 6 mg/kg, 130 mg (a lower dose than recommended), or placebo. patients enrolled in uc-1 had to have failed therapy with corticosteroids, immunomodulators or at least one biologic. a total of 51% had failed at least one biologic and 17% had failed both a tnf blocker and an integrin receptor blocker. of the total population, 46% had failed corticosteroids or immunomodulators but were biologic-naïve and an additional 3% had previously received but had not failed a biologic. at induction baseline and throughout the study, approximately 52% patients were receiving oral corticosteroids, 28% patients were receiving immunomodulators (aza, 6-mp, or mtx) and 69% patients were receiving aminosalicylates. the primary endpoint was clinical remission at week 8. clinical remission with a definition of: mayo stool frequency subscore of 0 or 1, mayo rectal bleeding subscore of 0 (no rectal bleeding), and mayo endoscopy subscore of 0 or 1 (mayo endoscopy subscore of 0 defined as normal or inactive disease and mayo subscore of 1 defined as presence of erythema, decreased vascular pattern and no friability) is provided in table 15. the secondary endpoints were clinical response, endoscopic improvement, and histologic-endoscopic mucosal improvement. clinical response with a definition of (≥ 2 points and ≥ 30% decrease in modified mayo score, defined as 3-component mayo score without the physician's global assessment, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1), endoscopic improvement with a definition of mayo endoscopy subscore of 0 or 1, and histologic-endoscopic mucosal improvement with a definition of combined endoscopic improvement and histologic improvement of the colon tissue [neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue]) are provided in table 15. in uc-1, a significantly greater proportion of patients treated with stelara ® (at the recommended dose of approximately 6 mg/kg dose) were in clinical remission and response and achieved endoscopic improvement and histologic-endoscopic mucosal improvement compared to placebo (see table 15 ). table 15: proportion of patients meeting efficacy endpoints at week 8 in uc-1 endpoint placebo n = 319 stelara ® infusion dose of stelara ® using the weight-based dosage regimen specified in table 4. n = 322 treatment difference and 97.5% ci adjusted treatment difference (97.5% ci) n % n % clinical remission clinical remission was defined as mayo stool frequency subscore of 0 or 1, mayo rectal bleeding subscore of 0, and mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability). 22 7% 62 19% 12% (7%, 18%) p < 0.001 bio-naïve an additional 7 patients on placebo and 9 patients on stelara ® (6 mg/kg) had been exposed to, but had not failed, biologics. 14/151 9% 36/147 24% prior biologic failure 7/161 4% 24/166 14% endoscopic improvement endoscopic improvement was defined as mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability). 40 13% 80 25% 12% (6%, 19%) bio-naïve 28/151 19% 43/147 29% prior biologic failure 11/161 7% 34/166 20% clinical response clinical response was defined as a decrease from baseline in the modified mayo score by ≥30% and ≥2 points, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1. 99 31% 186 58% 27% (18%, 35%) bio-naïve 55/151 36% 94/147 64% prior biologic failure 42/161 26% 86/166 52% histologic-endoscopic mucosal improvement histologic-endoscopic mucosal improvement was defined as combined endoscopic improvement (mayo endoscopy subscore of 0 or 1) and histologic improvement of the colon tissue (neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue). 26 8% 54 17% 9% (3%, 14%) bio-naïve 19/151 13% 30/147 20% prior biologic failure 6/161 4% 21/166 13% the relationship of histologic-endoscopic mucosal improvement, as defined in uc-1, at week 8 to disease progression and long-term outcomes was not evaluated during uc-1. rectal bleeding and stool frequency subscores decreases in rectal bleeding and stool frequency subscores were observed as early as week 2 in stelara ® -treated patients. study uc-2 the maintenance study (uc-2) evaluated 523 patients who achieved clinical response 8 weeks following the intravenous administration of either induction dose of stelara ® in uc-1. these patients were randomized to receive a subcutaneous maintenance regimen of either 90 mg stelara ® every 8 weeks, or every 12 weeks (a lower dose than recommended), or placebo for 44 weeks. the primary endpoint was the proportion of patients in clinical remission at week 44. the secondary endpoints included the proportion of patients maintaining clinical response at week 44, the proportion of patients with endoscopic improvement at week 44, the proportion of patients with corticosteroid-free clinical remission at week 44, and the proportion of patients maintaining clinical remission at week 44 among patients who achieved clinical remission 8 weeks after induction. results of the primary and secondary endpoints at week 44 in patients treated with stelara ® at the recommended dosage (90 mg every 8 weeks) compared to the placebo are shown in table 16. table 16: efficacy endpoints of maintenance at week 44 in uc-2 (52 weeks from initiation of the induction dose) endpoint placebo the placebo group consisted of patients who were in response to stelara ® and were randomized to receive placebo at the start of maintenance therapy. n = 175 clinical response was defined as a decrease from baseline in the modified mayo score by ≥30% and ≥2 points, with either a decrease from baseline in the rectal bleeding subscore ≥1 or a rectal bleeding subscore of 0 or 1. 90 mg stelara ® every 8 weeks n = 176 treatment difference and 95% ci n % n % clinical remission clinical remission was defined as mayo stool frequency subscore of 0 or 1, mayo rectal bleeding subscore of 0, and mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability). 46 26% 79 45% 19% (9%, 28%) p =<0.001 bio-naïve an additional 3 patients on placebo and 6 patients on stelara ® had been exposed to, but had not failed, biologics. 30/84 36% 39/79 49% prior biologic failure 16/88 18% 37/91 41% maintenance of clinical response at week 44 84 48% 130 74% 26% (16%, 36%) bio-naïve 49/84 58% 62/79 78% prior biologic failure 35/88 40% 64/91 70% endoscopic improvement endoscopic improvement was defined as mayo endoscopy subscore of 0 or 1 (modified so that 1 does not include friability). 47 27% 83 47% 20% (11%, 30%) bio-naïve 29/84 35% 42/79 53% prior biologic failure 18/88 20% 38/91 42% corticosteroid-free clinical remission corticosteroid-free clinical remission was defined as patients in clinical remission and not receiving corticosteroids at week 44. 45 26% 76 43% 17% (8%, 27%) bio-naïve 30/84 36% 38/79 48% prior biologic failure 15/88 17% 35/91 38% maintenance of clinical remission at week 44 in patients who achieved clinical remission 8 weeks after induction 18/50 36% 27/41 66% 31% (12%, 50%) p=0.004 bio-naïve 12/27 44% 14/20 70% prior biologic failure 6/23 26% 12/18 67% other endpoints week 16 responders to ustekinumab induction patients who were not in clinical response 8 weeks after induction with stelara ® in uc-1 were not included in the primary efficacy analyses for study uc-2; however, these patients were eligible to receive a 90 mg subcutaneous injection of stelara ® at week 8. of these patients, 55/101 (54%) achieved clinical response eight weeks later (week 16) and received stelara ® 90 mg subcutaneously every 8 weeks during the uc-2 trial. at week 44, there were 97/157 (62%) patients who maintained clinical response and there were 51/157 (32%) who achieved clinical remission. histologic-endoscopic mucosal improvement at week 44 the proportion of patients achieving histologic-endoscopic mucosal improvement during maintenance treatment in uc-2 was 75/172 (44%) among patients on stelara ® and 40/172 (23%) in patients on placebo at week 44. the relationship of histologic-endoscopic mucosal improvement, as defined in uc-2, at week 44 to progression of disease or long-term outcomes was not evaluated in uc-2. endoscopic normalization normalization of endoscopic appearance of the mucosa was defined as a mayo endoscopic subscore of 0. at week 8 in uc-1, endoscopic normalization was achieved in 25/322 (8%) of patients treated with stelara ® and 12/319 (4%) of patients in the placebo group. at week 44 of uc-2, endoscopic normalization was achieved in 51/176 (29%) of patients treated with stelara ® and in 32/175 (18%) of patients in placebo group.

be stored at room temperature up to 30°c (86°f) for a maximum single period of up to 30 days in the original carton to protect from light. record the date when the prefilled syringe is first removed from the refrigerator on the carton in the space provided. once a syringe has been stored at room temperature, it should not be returned to the refrigerator. discard the syringe if not used within 30 days at room temperature storage. do not use stelara ® after the expiration date on the carton or on the prefilled syringe.

rior reversible encephalopathy syndrome (pres) inform patients to immediately contact their healthcare provider if they experience signs and symptoms of pres (which may include headache, seizures, confusion, or visual disturbances) [see warnings and precautions (5.6) ] . immunizations inform patients that stelara ® can interfere with the usual response to immunizations and that they should avoid live vaccines [see warnings and precautions (5.7) ] . administration instruct patients to follow sharps disposal recommendations, as described in the instructions for use.